Discover verified cancer discoveries

Search and filter stories that passed editorial review. Evidence strength, regulatory status, and guideline position are shown separately and are never inferred from one another.

Filter discoveries

Results

Active filters:Clear all

22 verified discoveries match your filters.

Trial Watch: A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

Evidence stage: Later-Stage HumanRegulatory status: Investigational
Cancer type
Lung Cancer
Published
August 31, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.

Evidence stage: Later-Stage HumanRegulatory status: Investigational
Cancer type
Lung Cancer
Published
August 27, 2026

ClinicalTrials.gov confirms that this Phase 4 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Evidence stage: Later-Stage HumanRegulatory status: Investigational
Cancer type
Lung Cancer
Published
August 21, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Evidence stage: Later-Stage HumanRegulatory status: Investigational
Cancer type
Lung Cancer
Published
August 20, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

Evidence stage: Later-Stage HumanRegulatory status: Investigational
Cancer type
Lung Cancer
Published
August 19, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

Evidence stage: Later-Stage HumanRegulatory status: Investigational
Cancer type
Lung Cancer
Published
August 14, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Evidence stage: Later-Stage HumanRegulatory status: Investigational
Cancer type
Lung Cancer
Published
August 14, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

Trial Watch: Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

Evidence stage: Later-Stage HumanRegulatory status: Investigational
Cancer type
Lung Cancer
Published
August 14, 2026

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Primary source cited

Last reviewed

FDA converts tarlatamab’s accelerated approval to full approval for small cell lung cancer, on a real survival benefit

Evidence stage: High-Certainty EvidenceRegulatory status: FDA Approved
Cancer type
Lung Cancer
Published
August 13, 2026

In the randomized, open-label, phase 3 DeLLphi-304 trial, tarlatamab significantly extended overall survival compared with chemotherapy in patients with extensive-stage small cell lung cancer that had progressed after platinum-based chemotherapy…

Primary source cited

Last reviewed